Abstract 1204TiP
Background
Patients (pts) with extensive-stage (ES) SCLC or extra-pulmonary grade 3 (G3) NEC rapidly develop progressive disease after 1st -line cytotoxic chemotherapy, and efficacious 2nd -line treatment options are needed. Lysine Specific Demethylase 1 (LSD1, aka KDM1A) is involved in repressing transcription by removing methyl groups from mono- and di-methylated lysine 4 of histone 3, epigenetic hallmarks commonly associated with actively transcribed genes. LSD1 over-expression is associated with tumor progression and worse prognosis, and its inhibition reduces cancer cell growth, migration, and invasion. The epigenetic drug iadademstat (aka ORY-1001 or iada) is a highly potent and selective LSD1 inhibitor (LSD1i) in phase 2 clinical development for malignant indications. Iada and other LSD1is are effective in in vitro and in vivo models of SCLC by preventing INSM1 recruitment of LSD1 which results in NOTCH signaling activation, reduced NE differentiation and tumor growth inhibition. Additionally, LSD1is have been implicated in reversing chemoresistance, synergizing with paclitaxel, and enhancing immunostimulatory responses by increasing MHC-Class I expression, IFN-Type I responses and T-cell infiltration and activity.
Trial design
NCT05420636 is a multi-center, non-randomized phase II study to treat up to 42 pts with iada (150 mg oral, 5d on-2d off every week) and paclitaxel (80 mg/m2 IV weekly) in 21 day cycles. Eligibility includes adult pts with metastatic/unresectable SCLC (cohort 1) or extra pulmonary G3 NEC or metastatic/unresectable prostate or bladder cancer with G3 NE or small cell component (cohort 2), who have received 1 to 3 prior lines of therapy and progressed on or after platinum-based chemotherapy. Pts must have measurable disease, normal organ, and marrow function, stable brain mets, ECOG status ≤1 and not have received prior taxanes for metastatic disease. The primary endpoint is ORR per RECIST 1.1; secondary endpoints include rate of ≥ grade 3 toxicities, PFS, OS and DoR. Exploratory endpoints include host inflammatory cytokine and immune profile, and epigenomic and genomic analysis of tumor and peripheral blood samples.
Clinical trial identification
NCT05420636.
Editorial acknowledgement
Legal entity responsible for the study
Fox Chase Cancer Center.
Funding
Oryzon.
Disclosure
N. Vijayvergia: Non-Financial Interests, Institutional, Local PI: BMS, ITM; Financial Interests, Personal, Advisory Board: Taiho, ITM; Non-Financial Interests, Institutional, Principal Investigator: Oryzon, Puma; Non-Financial Interests, Personal, Advisory Role: Rayze Bio. P. Ghatalia: Non-Financial Interests, Institutional, Research Funding: BMS, Oryzon, Merck. D. Faller: Financial Interests, Personal, Full or part-time Employment: Oryzon. A. Limon: Financial Interests, Personal, Full or part-time Employment: Oryzon. H.P. Soares: Financial Interests, Personal, Advisory Board: Tersera, Ipsen, AstraZeneca, Novartis, ITM. J. whetstine: Financial Interests, Institutional, Research Funding: Oryzon, Salarius Pharma; Financial Interests, Personal, Advisory Board: QSonica, Vyne Therapeutics, Daiichi Sankyo, Lily Asia Ventures. H. Borghaei: Financial Interests, Personal, Advisory Board: BMS, Genentech, Eli-Lilly, Merck, EMD-serono, AstraZeneca, Novartis, Genmab, Regeneron, Amgen, Takeda, PharmaMar, Jazz Pharma, Mirati, Daiichi, Guardant, Natera, Oncocyte, BeiGene, iTeo, Boehringer Ingelheim, Puma, BerGenbio, Janssen; Financial Interests, Personal, Other, Training discussion: Pfizer; Financial Interests, Personal, Other, DSMB: Novartis; Financial Interests, Institutional, Other, Clinical trial support: BMS, Amgen; Financial Interests, Personal, Stocks/Shares, Options for scientific advisory role: Sonnetbio; Financial Interests, Personal, Stocks/Shares, Options for scientific advisory board: Nucleai, Inspira (Rgenix); Financial Interests, Institutional, Trial Chair, Investigator initiated trial support: BMS; Financial Interests, Institutional, Coordinating PI, Investigator initiated trial support: Amgen, Lilly; Financial Interests, Personal and Institutional, Trial Chair, Chair steering committee: Miratti; Financial Interests, Personal and Institutional, Steering Committee Member: Amgen, AstraZeneca; Financial Interests, Personal, Steering Committee Member, Also trial support: BMS; Other, Other, DSMB: Novartis, Takeda, Incyte, Springworks. All other authors have declared no conflicts of interest.
Resources from the same session
1807P - Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status
Presenter: Nobuaki Matsubara
Session: Poster session 14
1808P - Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m<sup>2</sup>) versus every 3 weeks (25 mg/m<sup>2</sup>) in the CABASTY phase III trial
Presenter: Stephane Oudard
Session: Poster session 14
1809P - Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
Presenter: Nicole Brighi
Session: Poster session 14
1810P - Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
Presenter: Michael Morris
Session: Poster session 14
1811P - Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study
Presenter: Andre Fay
Session: Poster session 14
1813P - Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
Presenter: Andrew Laccetti
Session: Poster session 14
1814P - First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France
Presenter: Anne-Laure Giraudet
Session: Poster session 14
1815P - Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1
Presenter: Elena Castro
Session: Poster session 14